Blood lipids and prostate cancer: a Mendelian randomization analysis.
Bull, CJ, Bonilla, C, Holly, JM, Perks, CM, Davies, N, Haycock, P, Yu, OH, Richards, JB, Eeles, R, Easton, D, Kote-Jarai, Z, Amin Al Olama, A, Benlloch, S, Muir, K, Giles, GG, MacInnis, RJ, Wiklund, F, Gronberg, H, Haiman, CA, Schleutker, J, Nordestgaard, BG, Travis, RC, Neal, D, Pashayan, N, Khaw, KT, Stanford, JL, Blot, WJ, Thibodeau, S, Maier, C, Kibel, AS, Cybulski, C, Cannon-Albright, L, Brenner, H, Park, J, Kaneva, R, Batra, J, Teixeira, MR, Micheal, A, Pandha, H, Smith, GD, Lewis, SJ and Martin, RM (2016) Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer medicine, 5 (6). pp. 1125-1136.
Available under License : See the attached licence file.
Download (33kB) | Preview
Download (368kB) | Preview
Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer cases and 22,133 controls from 22 studies within the international PRACTICAL consortium were analyzed. Allele scores based on single nucleotide polymorphisms (SNPs) previously reported to be uniquely associated with each of low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels, were first validated in an independent dataset, and then entered into logistic regression models to estimate the presence (and direction) of any causal effect of each lipid trait on prostate cancer risk. There was weak evidence for an association between the LDL genetic score and cancer grade: the odds ratio (OR) per genetically instrumented standard deviation (SD) in LDL, comparing high- (≥7 Gleason score) versus low-grade (<7 Gleason score) cancers was 1.50 (95% CI: 0.92, 2.46; P = 0.11). A genetically instrumented SD increase in TGs was weakly associated with stage: the OR for advanced versus localized cancer per unit increase in genetic risk score was 1.68 (95% CI: 0.95, 3.00; P = 0.08). The rs12916-T variant in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) was inversely associated with prostate cancer (OR: 0.97; 95% CI: 0.94, 1.00; P = 0.03). In conclusion, circulating lipids, instrumented by our genetic risk scores, did not appear to alter prostate cancer risk. We found weak evidence that higher LDL and TG levels increase aggressive prostate cancer risk, and that a variant in HMGCR (that mimics the LDL lowering effect of statin drugs) reduces risk. However, inferences are limited by sample size and evidence of pleiotropy.
|Divisions :||Faculty of Health and Medical Sciences > School of Biosciences and Medicine|
|Date :||June 2016|
|Identification Number :||https://doi.org/10.1002/cam4.695|
|Copyright Disclaimer :||© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/|
|Uncontrolled Keywords :||Cholesterol, Mendelian randomization, Prostate cancer, Statins|
|Depositing User :||Symplectic Elements|
|Date Deposited :||23 Aug 2016 11:09|
|Last Modified :||05 Sep 2016 08:03|
Actions (login required)
Downloads per month over past year